31,741 Shares in Edwards Lifesciences Co. (NYSE:EW) Purchased by Generali Asset Management SPA SGR

Generali Asset Management SPA SGR acquired a new position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 31,741 shares of the medical research company's stock, valued at approximately $2,350,000.

Other large investors have also recently bought and sold shares of the company. FSA Wealth Management LLC bought a new stake in Edwards Lifesciences in the third quarter valued at $30,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in Edwards Lifesciences in the fourth quarter worth approximately $30,000. Prospera Private Wealth LLC acquired a new stake in Edwards Lifesciences in the third quarter valued at approximately $32,000. Avior Wealth Management LLC increased its holdings in shares of Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock valued at $35,000 after acquiring an additional 308 shares in the last quarter. Finally, Roble Belko & Company Inc acquired a new position in shares of Edwards Lifesciences during the fourth quarter worth approximately $46,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Price Performance

Shares of NYSE EW traded up $0.97 during midday trading on Monday, hitting $71.43. 3,603,111 shares of the company's stock were exchanged, compared to its average volume of 4,612,597. The business's fifty day moving average price is $71.42 and its two-hundred day moving average price is $70.38. The company has a market cap of $41.99 billion, a price-to-earnings ratio of 10.25, a PEG ratio of 4.82 and a beta of 1.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12.

Remove Ads

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, research analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 500 shares of the stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the transaction, the vice president now owns 23,189 shares of the company's stock, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Steven R. Loranger sold 5,739 shares of the company's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the sale, the director now owns 60,372 shares of the company's stock, valued at approximately $4,613,628.24. The trade was a 8.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 51,303 shares of company stock worth $3,715,776. 1.29% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

EW has been the subject of a number of recent research reports. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and boosted their price target for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. Barclays lifted their price target on Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. Morgan Stanley raised their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research note on Wednesday, February 12th. Wolfe Research downgraded shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a report on Wednesday, February 12th. Finally, Bank of America upgraded shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $82.00 to $90.00 in a report on Monday, December 16th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.